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Fbxo7 is a key player in the differentiation and function of numerous blood cell types, and in neurons,
oligodendrocytes and spermatocytes. In an effort to gain insight into the physiological and pathological
settings where Fbxo7 is likely to play a key role, we sought to define the transcription factors which
direct FBXO7 expression. Using sequence alignments across 28 species, we defined the human FBXO7
promoter and found that it contains two conserved regions enriched for multiple transcription factor
binding sites. Many of these have roles in either neuronal or haematopoietic development. Using various
FBXO7 promoter reporters, we found ELF4, Pax5 and c-Myb have functional binding sites that activate
transcription. We find endogenous Pax5 is bound to the FBXO7 promoter in pre-B cells, and that the
exogenous expression of Pax5 represses Fbxo7 transcription in early pro-B cells.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
F-box proteins (FBP) are exchangeable subunits within Skp1-
Cullin1-F-box protein (SCF)-type E3 ubiquitin ligases. These en-
zymes conjugate a 76aa ubiquitin peptide onto proteins, and this
post-translational modification can precipitate that target’s
degradation, change of localisation or activity. Fbxo7 is one of
~70 F-box domain-containing proteins, which are receptors for
SCF-E3 ligases. However, Fbxo7 also functions outside of canonical
ubiquitin-dependent pathways, for example, acting as scaffolds for
other regulatory proteins [1]. At a physiological level, mis-
regulation of Fbxo7 has been implicated in human diseases with
disparate aetiologies, including neurological diseases, anaemia and
cancer, attesting to its pleiotropic role in numerous cell types [2e4].
Fbxo7 has hundreds of potential substrates making the discov-
ery of the critical pathways affected by its mis-regulation in path-
ological settings very challenging [5]. At a molecular level, Fbxo7
affects many processes including, the cell cycle, enhancing cyclin D/
Cdk6 activity by acting as a scaffold for their assembly and stabil-
ising the cyclin-dependent kinase inhibitor, p27 [6]; the regulation
of stress-induced mitophagy via the PINK1/Parkin pathway [7]; NF-
kB signalling [8e10], and BMP signalling via NRAGE-TAK1-TAB1r Inc. This is an open access articlcomplex formation [11]. In addition, Fbxo7 ubiquitinates protea-
somal subunits, like PSMA2, affecting the assembly of proteasomes,
ribosomal subunits, like stress-responsive subunit RPL23, to induce
p53 transcriptional responses, and most recently the kinase, PINK1
[5,12e17]. In addition, Fbxo7 is essential for male fertility, and this
is attributed to the stabilisation of a proteasomal regulator and
trafficker, PI31 [18e22]. The severity of phenotypes in neurons,
erythrocytes, spermatocytes and lymphocytes demonstrate the
essentialness of Fbxo7-regulated pathways.
We and others have reported the important role of Fbxo7 in the
development and differentiation of B and T lymphocytes [22e24].
In addition, Fbxo7 can be oncogenic as its over-expression on a
background of p53 mutation promotes T cell lymphomagenesis
[25]. Recently, a number of high-resolution studies of transcription
factor (TF) networks reveal the TFs that function in the normal
expansion and differentiation of immature progenitor cells are
often dysregulated in leukaemia and lymphoma [26e30]. Since
Fbxo7 and its proto-oncogenic partners, CDK6 and cyclin D2 and D3
are key cell cycle regulators in B and T cells, we investigated
whether any of the lineage-specifying haematopoietic TFs control
the transcription of Fbxo7. We sought to identify potential TF
binding sites within the FBXO7 promoter and to investigate their
regulation of Fbxo7 expression. We identified several promoter
elements for TFs, including ELF4, c-Myb and Pax5, which is amaster
regulator of B cell differentiation, neural development, and
spermatogenesis.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Promoter alignment. Transcription start sites (TSS) within the
NCBI RefSeq FBXO7 gene sequence were identified using Eponine
software. Fbxo7 orthologues from 28 mammalian species were
aligned using the USCS Comparative Genomics 28-way vertebrate
alignment and conservation track, and regions of conservation
identified. Sequences 10 kb upstream to 10 kb downstream of the
gene start site were analysed until conserved regions of similarity
stopped. Putative conserved TF binding sites were then identified
using MatInspector software. Sites found in more than half of the
species were annotated. Data was presented in Clustal W format.
This analysis was performed by Dr Michael Mitchell of the CRUK
Bioinformatics & Biostatistics Service.
FBXO7 promoter cloning. A 1.7 kb DNA region containing se-
quences approximately 1.3 kb upstream to 0.4 kb downstream of
the FBXO7 TSS was amplified by PCR from genomic DNA, and
subcloned into pGEM-T Easy vector (Promega). Luciferase reporter
constructs were amplified from this plasmid, including a 1.5 kb
region (containing the full length FBXO7 promoter, termed Fbxo7-
luc), a 0.5 kb proximal promoter region (proximal Fbxo7-luc), and
a 0.6 kb distal promoter region (distal Fbxo7-luc), which were sub-
cloned into pTA-luc (Clontech). Site-directedmutagenesis was used
to mutate the Pax5 and ETS binding sites. All mutations were
verified by sequencing.
Cell culture and biochemistry. U2OS, Eco Phoenix cells and B
cell lines (Nalm6, Ba/F3, Raji, A20) were maintained as in Ref. [23].
Immunoblotting was performed as in Ref. [3].
Luciferase assay. U20S cells were transfected with 200 ng of
reporter plasmid DNA, 200 ng of pEF-LacZ, and 200 ng of
mammalian expression vectors. After 48 h cells were harvested,
and luciferase assays performed as in Ref. [5].
RT-qPCR. Experiments were performed as in Ref. [3]. Expression
was normalised to cyclophilin levels, and values expressed relative
to vector control cells.
Chromatin immunoprecipitation. Chromatin immunoprecipi-
tation (ChIP) was performed as recommended using the ChIP-IT
Express kit (Active Motif). 100 mL of sheared chromatin was
immunoprecipitated with 3 mg anti-Pax5, IgG or anti-RNA poly-
merase II (Human ChIP-ITcontrol kit; ActiveMotif) and precipitated
by magnetic protein G beads.
Semi-quantitative and quantitative PCR. PCR primer pairs
encompassed the putative Pax5 binding site in FBXO7, and that
previously published for the CD19 promoter [31], as well as nega-
tive control GAPDH primers supplied in the ChIP-IT control kit.
Primer pairs were used in triplicate PCR reactions and performed as
in Ref. [3].
Expression constructs. Pax5 and ELF4 cDNAs were sub-cloned
in frame to FLAG or T7 epitope tags in pcDNA3 (Invitrogen). A
Pax5 expression construct, pX-13, was provided by Dr F Baumann-
Kubetzko. Full length pCB6-MEFwith ELF4 sequences was provided
by Dr MA Suico. A Pax5 retroviral construct was generated by sub-
cloning into MCSV-IRES-GFP. Pax5 shRNA sequences targeting
endogenous mouse Pax5 mRNA were from the RNAi Codex data-
base (codex.cshl.edu). shRNA vectors were cloned into MSCV-
LTRmiR30-IRES-GFP. All vectors were verified by sequencing.
Antibodies and primers used in this study are listed in Sup-
plementary Information.
Results
The FBXO7 promoter contains two TF islands
To investigate the transcriptional regulation of FBXO7, its pro-
moter was analysed for the presence of TF binding sites. Sequence42alignment of 28 mammalian species identified a region of
conserved sequence similarity upstream of the FBXO7 transcription
start sites (TSS). Consequently, the FBXO7 promoter was delineated
as starting 1300bp upstream from the start of exon 1, to 100bp
downstream, numbered according to the human FBXO7 gene
(1300 to þ100). Within this region, two clusters of conserved TF
binding sites were identified, approximately 1 kb apart. One island
in the distal promoter region was 125bp in length (1275
to 1150), while the other in the proximal promoter region was
400bp in length and overlapped the TSS and start of exon 1 (300
to þ100). These islands contained the majority of TF binding sites,
and selected regions from 13 of the species surveyed are shown in
Fig. 1A. 32 putative binding sites were identified for 24 different TFs
(17 in the distal region; 15 in the proximal region). We identified
‘core’ promoter elements, including two CCAAT boxes on opposite
strands at 1257 and 1198 in the distal region, and a GC box,
identified as an Sp1 binding site, in the proximal regionwithin exon
1 (þ81). No TATA box was identified, and the proximal region was
GC rich, suggesting the FBXO7 promoter is associated with a CpG
island. In addition to ubiquitously expressed TFs, like activator
protein (AP) and E2Fs, we identified multiple consensus sites for
TFs with roles in haematopoiesis and neuronal development (ETS,
c-Myb, DMTF, Pax5, Myt1, NeuroD, NRF1, CLOX, ZF5F).
The FBXO7 reporter is activated by ETS factors, including ELF4
To test putative binding sites, FBXO7 reporters were generated.
Full length FBXO7 promoter (1422 to þ164), as well as either the
distal (1558 to 1030) or proximal (375 to þ164) regions were
cloned into pTA-luc luciferase plasmid (Fig. 1B). Within the distal
region, we identified two ETS binding sites (EBS), shown in Fig. 1A
as ETSF. The consensus site contains a core GGAA sequence, but
flanking sequences and co-factor binding impart specificity for
particular ETS factors. We tested a panel of ETS factors (ETS1, ETS2,
Fli1, ELF4, ELF1, and PU.1) by co-transfecting them with the distal
reporter (Distal Fbxo7-luc) or a control (pTA-luc) into U20S cells
(Fig. 2A). The transfection of ELF4, ELF1 and Fli1 increased tran-
scription of the pTA-luc control reporter, indicating the presence of
cryptic response elements for three of the six ETS factors tested.
However, transfection of this panel of ETS factors with the distal
Fbxo7-luc reporter showed that ELF4 and ELF1, and also ETS1 and
ETS2, and significantly increased activation of the reporter (p <
0.05), above the background level of activation seen in the control
reporter. These data suggest the presence of functional EBSs in the
distal promoter. We noted both EBSs contain a WGGA (where W is
A/T) sequence, which matches the consensus site for ELF4,
consistent with its higher activation of the reporter. Mutation of the
EBSs significantly reduced ELF4 transactivation (p < 0.05) (Fig. 2B),
indicating that ELF4 utilised these sites to activate the distal
reporter.
Fbxo7 inhibits ELF4 trans-activation
Lui and co-workers reported Fbxo7 and ELF4 physically interact
[32], which suggests Fbxo7 may affect ELF4 transactivation. To test
this, ELF4 was co-transfected with either WT Fbxo7 or a mutant
lacking the F-box domain (DF-box), and the full-length luciferase
reporter into U2OS cells. ELF4 activation of the reporter was
inhibited 80% by the addition of WT or mutant Fbxo7 (Fig. 2C),
indicating Fbxo7 inhibits ELF4 transactivation and does so in a
ubiquitin-independent manner. We next tested whether this effect
was dependent on ELF4 or a general effect on FBXO7 and other
reporters, by transfecting Fbxo7 and measuring luciferase expres-
sion from other reporters. As before, we found Fbxo7 significantly
inhibited the full length Fbxo7-luc, but not the Cre-luc or E2F-luc
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these results suggests that Fbxo7 may bind to other ETS factors.
Together, these data suggest Fbxo7 can inhibit transcription from
its own promoter in an SCF ligase-independent manner.
An FBXO7 gene reporter is activated by Pax5 and c-Myb
ETS factors act in concert with other TFs, like Pax5.We identified
a Pax5 consensus site in the proximal region. To test its function-
ality, U20S cells were co-transfected with a Pax5 expression
construct or a control and the reporters, and luciferase assays were
performed. A dose-dependent increase in luciferase activity was
detected with increasing Pax5 expression from the full length and
proximal FBXO7 constructs (Fig. 3A), with a more limited response
from the distal reporter. This suggests that Pax5 activation of the
full-length promoter is predominantly via the proximal region. We
also mutated the Pax5 binding site within the proximal reporter
(Fig. 3B) and tested the effect (Fig. 3C). Expression of Pax5 resulted
in a 40-fold induction of luciferase activity from the proximal re-
porter, whereas Pax5 activation of the mutant reporter was
significantly reduced by 37% (Fig. 3C). These data argue Pax5 acti-
vation of the reporter occurs at the Pax5 binding site. We next
tested whether Pax5 activation was modulated by ETS family
members. As in Fig. 3A, Pax5 activated the full-length reporter
(Fig. 3D). However, when Fli1 was co-transfected with Pax5, lucif-
erase levels increased by 70% over Pax5 alone, and 340% more than
Fli1 alone. In contrast, addition of ETS1 or PU.1 inhibited Pax5
activation by 40% and 60%, respectively.
A c-Myb binding site overlaps the Pax5 binding site (Fig.1A), and
c-Myb has also been shown to influence Pax5 activity [33,34]. To
test the c-Myb binding site, we transfected c-Myb along with either
theWTormutated proximal reporter constructs (Fig. 3B) and found
c-Myb activated the proximal region by 12-fold (Fig. 3C). Further-
more, the mutated reporter, which contained one altered base pair
within the consensus c-Myb site, showed decreased activationwith
c-Myb by 40% compared to the WT promoter. As Pax5 and c-Myb
both activated the proximal reporter through an overlapping
binding site, we tested whether they had a synergistic or compet-
itive effect on transactivation. When transfected together, Pax5 and
c-Myb activated the proximal reporter more than 8-fold over c-
Myb alone, and over 13-fold than Pax5 alone (Fig. 3E), suggesting
they act synergistically through this site. These data indicate that
Pax5 together with ETS and c-Myb TFs transactivate the FBXO7
reporters.
Endogenous Pax5 binds to the Fbxo7 promoter
As Pax5 and c-Myb are both involved in B cell development, a
screen of c-Myb and Pax5 protein expression was conducted in a
panel of B cell tumour lines originating from B cells at different
stages of maturation (Fig. 4A). Both proteins were noted to be
expressed in the earlier stages of B cell development, and their
expression decreased as B cells matured, consistent with roles in B
cell maturation. Immunoblotting for Fbxo7 expression, we noted
that Fbxo7 correlated with Pax5, but not necessarily c-Myb. For
example, Fbxo7 expression was readily detected in Nalm6 and Raji
cell lysates, but Raji cells had no detectable c-Myb expression
(Fig. 4B).Fig. 1. Sequence alignment of 13 mammalian species (A, upper) showing 1275 to 1176 of t
proximal TF island which covers 300 to þ100, numbered according to the human sequence
forward strand, and below the alignment on the reverse strand. Conserved bases are show
human FBXO7. The promoter (green) was defined by sequence alignment of several spec
(brackets). The 50 UTR (white), coding sequences (blue), and first intron (yellow) are indicate
this figure legend, the reader is referred to the Web version of this article.)
44Wenext testedwhether Pax5was present at the Fbxo7 promoter
in maturing B cells, using chromatin immunoprecipitation (ChIP)
assays. The CD19 promoter, a Pax5 target, and GAPDH, which does
not contain a consensus Pax5 site, were selected as promoter
controls, and antibodies to RNA polymerase II and normal serum
IgG were used as immunoprecipitation controls. ChIP experiments
were performed in Nalm6 cells, which showed high expression of
Pax5, Fbxo7, and c-Myb. Immunoprecipitated DNAwas analysed by
qPCR, and DNA enrichment expressed as a percentage of input DNA
to normalize for differences in PCR efficiency. The FBXO7 promoter
was enriched 4-fold in DNA immunoprecipitated using Pax5 anti-
body compared to IgG only, and 32-fold over the amount of GAPDH
promoter region immunoprecipitated by Pax5 antibody (Fig. 4C).
This was despite a significant enrichment of the GAPDH promoter
by RNA polymerase II antibodies. Enrichment of the FBXO7 pro-
moter in Pax5 immunoprecipitates, and enrichment of the FBXO7
and GAPDH promoter in RNA polymerase II immunoprecipitates
were significantly increased (p < 0.01) compared to IgG levels.
Unexpectedly, there was no significant enrichment of the CD19
promoter in Pax5 or RNA polymerase II immunoprecipitates, sug-
gesting CD19 was not transcribed. We confirmed the lack of CD19
expression by flow cytometry of the cells with a fluorescently
labelled anti-CD19 antibody (data not shown). Similar enrichment
of the FBXO7 promoter in Pax5 immunoprecipitates were found in
murine A20 cells. These data indicate the Pax5 binding site in the
FBXO7 promoter is a functional TF binding site in B cells and suggest
Pax5 directly regulates FBXO7 expression.Early expression of Pax5 reduced Fbxo7 expression in pro-B cells but
not in later stage B cells
We then performed experiments to alter the expression of Pax5
in Nalm6 cells, which expressed Pax5, c-Myb and Fbxo7. Nalm6
cells were transduced with retroviruses encoding Pax5 to further
increase its expression; however, no changes in Fbxo7 mRNA levels
were observed (Fig. 4D). Similar negative results were seen in
A20 cells (data not shown). We also tested the effect of reducing
Pax5 expression using a short hairpin construct in Nalm6 cells. The
shRNA caused an approximate 70% reduction in Pax5 mRNA levels,
and although there was a small increase in Fbxo7 expression, this
was not a statistically significant change (Fig. 4E). We considered
whether c-Myb might regulate Fbxo7 expression in Nalm6 cells, so
we also targeted its expression using a shRNA against c-Myb and
expressing GFP. Cells were transduced with viruses expressing
shRNAs and then selected and cloned by limiting dilution. Cell ly-
sates were assayed by immunoblotting (Fig. 4F). Surprisingly,
reduction of c-Myb expression also reduced Pax5 expression, sug-
gesting c-Myb stabilises Pax5 expression; however, despite re-
ductions in the levels of both transcription factors, there was no
effect on Fbxo7 levels in Nalm6 cells.
We tested whether Pax5 would influence Fbxo7 transcription in
earlier stage B cells lacking endogenous Pax5 expression. Ba/F3 pro-
B cells were infected with retroviruses encoding Pax5 and GFP.
Total RNAwas harvested fromGFPþ ve cells, andmRNA levelswere
assayed using RT-qPCR. We observed a 50% reduction in Fbxo7
mRNA levels when Pax5 expression was introduced (Fig. 4G). Thus,
ectopic expression of Pax5 in a pro-B cell affected Fbxo7 expression,
while over-expression in a pre-B cell did not. Our data arehe distal TF island which covers 1275 to 1151, and (A, lower) from 66 to þ35 of the
from the start of exon 1. Putative TF binding sites are listed above the alignment on the
n in blue and conserved pyrimidines or purines, in green. (B) Schematic of the start of
ies (see M&M). Several TF binding sites were identified within conserved TF islands
d. Luciferase reporters (red) are below. (For interpretation of the references to colour in
Fig. 2. (A) Luciferase assay of cell lysates from U2OS cells transfected with distal Fbxo7-luc, or pTA-luc empty vector, along with a panel of six ETS family members. Luciferase values
in triplicate, were background corrected with non-transfected cell lysate values, and normalised to co-transfected b-galactosidase levels, and expressed relative to empty vector ().
*p < 0.05 compared to the relevant empty control levels, n ¼ 3. (B) Luciferase assay showing ELF4 activation of the empty vector, distal Fbxo7-luc and mutated distal Fbxo7-luc
reporter constructs, n ¼ 3. Below: the two ELF4 consensus sites in the FBXO7 promoter are shown in blue, and mutated base pairs in red. (C) Luciferase assays showing ELF4
activity on the Fbxo7-luc reporter in the presence of exogenous Fbxo7 or ligase-dead mutant Fbxo7-DFbox. (D) Luciferase assays in cells transfected with a panel of luciferase
reporters, with or without Fbxo7, n ¼ 3. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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promoter and repressing transcription.Discussion
To investigate Fbxo7 transcriptional regulation, we defined the
human FBXO7 promoter, as a conserved promoter region
between 1300 and þ 100 bp from the start of exon 1. Within the
promoter two conserved TF islands (300 to þ100 and 1275
to 1150) were identified. A similar proximal promoter was re-
ported in the pig, although it was limited to 1000 bp upstream of
the TSS [35]. Although no TATA box was identified, as for the pig,
the CCAAT and GC boxes may constitute part of the core promoter
of FBXO7. Consistent with this, analysis of the publicly available
gene annotation database Encyclopaedia of DNA Elements
(ENCODE; http://genome.ucsc.edu/ENCODE/) [36], suggests that
the proximal region, along with exon 1 of FBXO7 lies within a CpG
island, H3K4 tri-methylation region and DNase I hypersensitivity
site, indicating these sequence form the core FBXO7 promoter.
Given the key roles of the Fbxo7 in blood, we investigated TF
binding sites with known roles in haematopoiesis. These included
twin ETS binding sites in the distal region of FBXO7 and overlapping
Pax5 and c-Myb sites in the proximal region.We found Pax5, c-Myb
and the ETS family members, ELF4 and ELF1, were the strongest45activators of a synthetic FBXO7 reporter. Interestingly, Fbxo7 has
been previously reported to directly interact with ELF4. Our data
indicates that Fbxo7 inhibits ELF4 activation of the FBXO7 reporter,
an activity independent of its ubiquitin ligase function, suggesting a
negative feedback mechanism. Also, since Fbxo7 did not inhibit
other luciferase reporters, this suggests Fbxo7 specifically inhibits
its own transcription.
The FBXO7 reporter was also transactivated by Pax5, whose
expression is largely restricted to B cells. Using ChIP assays, we
found that endogenous Pax5 was bound to the proximal region of
FBXO7 in both the mature B cell line, A20, and a leukaemic pre-B
cell line, Nalm6, indicating a functional Pax5 binding site. Despite
this, only the exogenous expression of Pax5 in Ba/F3 cells caused a
change in FBXO7 mRNA expression, repressing transcription. We
believe this difference between reporter assays and endogenous
transcription reflects the chromatin nature of transcriptional acti-
vation. It is known that Pax5 acts in concert with other TFs such as
ETS factors [33,37]. Pax5 recruits ETS factors, Net and Elk-1, to the
mb-1 promoter in pre-B cells to increase DNA binding, whereas PU.1
recruits Grg4 to Pax5-occupied promoters where Pax5 represses
transcription [37]. We found several ETS factors modulated Pax5
transactivation of an FBXO7 reporter, including Fli1 which increased
transcription, and ETS1 and PU.1 which inhibited it. Interestingly, a
study of TF networks in haematopoietic cells using combined data
Fig. 3. (A) Luciferase assay with various FBXO7 reporters and increasing doses of Pax5. (B) A c-Myb binding site overlaps a Pax5 binding site. Shown are the Pax5 binding site (blue),
with bases in the FBXO7 promoter matching the consensus for c-Myb (green), and the mutated bases in the Proximal FBXO7 reporter (red). (C) Luciferase assay on U2OS cell lysates
co-transfected with Pax5 or c-Myb, and the empty, WT, or mutated proximal Fbxo7-luc reporters. (D) Luciferase assay showing activation of various Fbxo7 luciferase vectors by
vector only (vec) or exogenous ETS family members, with (þ, dark grey) or without (-, light grey) Pax5. (E) Luciferase assay on U2OS cell lysates co-transfected with Pax5 or c-Myb,
in combination, with the proximal Fbxo7-luc reporter. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 4. (A) Human B cell tumour lines analysed by immunoblotting for the expression of Pax5 and c-Myb. ALL ¼ Acute lymphocytic leukaemia, BL ¼ Burkitt’s lymphoma, DLBCL ¼
diffuse large B cell lymphoma. (B) Immunoblotting of cell lysates from murine Ba/F3 pro-B cell, pre-B cell, and mature B cell lines for Fbxo7, Pax5 and c-Myb expression. (C) Pax5
chromatin immunoprecipitation of the FBXO7 promoter in Nalm6 cells. Values were then expressed as a percentage relative to input. **p < 0.01 compared to relevant control IgG
levels. n ¼ 2 independent experiments with triplicate qPCR reactions. (D) Graphs of mRNA expression of Nalm6 cells transduced to over-express Pax5 (grey bars) or empty vector
(black bars), n ¼ 2. (E) Graph of mRNA expression in Nalm6 cells transduced to express a shRNA construct targeting Pax5 (grey bars), or empty vector (black bars). Pax5 and Fbxo7
mRNA levels were analysed by RT-qPCR, normalised to cyclophilin A levels and expressed relative to empty vector control cells. (F) Immunoblotting of Nalm6 cell lysates transduced
with shRNA constructs targeting c-Myb expression, n ¼ 2. (G) Graphs of mRNA expression of Ba/F3 cells transduced to over-express Pax5 (grey bars) or empty vector (black bars),
n ¼ 2.
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highlighting that PU.1 also regulates FBXO7 expression [38]. Pax5
also enlists other TFs like c-Myb, e.g., Pax5 recruits c-Myb to the
RAG-2 promoter in B cells [33], and our data indicate c-Myb may47affect Pax5 levels and thus indirectly affect transcription at the
FBXO7 promoter.
Although Pax5, c-Myb, ETS, have important roles in haemato-
poiesis, c-Myb and Pax5 also have roles in neural progenitor cell
R. Harris, S. Randle and H. Laman Biochemical and Biophysical Research Communications 554 (2021) 41e48proliferation [39], and early midbrain development [40], respec-
tively. Fbxo7 is expressed in mouse adult brain [15], so whether
these TF sites are active during brain development warrant further
study. Intriguingly, given Fbxo7’s role in Parkinson’s disease, a site
for nuclear respiratory factor 1 (NRF1) was also found in its pro-
moter. This TF is associated with mitochondrial function and
metabolism, neurite outgrowth, and the ‘bounce back’ of protea-
some transcription under proteotoxic stress [41e44]. That multiple
TFs co-operate to regulate Fbxo7 expression and are involved both
in cell differentiation and stress-responsive functions points to a
model wherein the proteins that specify cellular lineages and
mature cell types also have a role in maintaining their health when
they come under stress.
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